Baird raised the firm’s price target on Agenus (AGEN) to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Strategic Collaboration Between Agenus and Zydus Lifesciences Boosts Financial Position and Product Development
- Agenus upgraded to Buy from Neutral at H.C. Wainwright
- Agenus selling U.S. manufacturing facilities to Zydus
- Agenus, Zydus enter $141M collaboration for BOT/BAL production orders
- Agenus presents new translational data at 2025 ASCO meeting